Relebactam
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Relebactam |
| DrugBank ID | DB12377 |
| Brand Names (EU) | Relebactam |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.43% |
Approved Indication (EMA)
See EMA product information
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pyelonephritis | 99.43% | DL |
| 2 | polyclonal hyperviscosity syndrome | 99.22% | DL |
| 3 | hyperamylasemia | 99.22% | DL |
| 4 | congenital analbuminemia | 99.08% | DL |
| 5 | blood group incompatibility | 98.92% | DL |
| 6 | premalignant hematological system disease | 98.81% | DL |
| 7 | monoclonal gammopathy | 98.76% | DL |
| 8 | hematological disease associated with an acquired peripheral neuropathy | 98.59% | DL |
| 9 | hematopoietic and lymphoid system neoplasm | 98.48% | DL |
| 10 | congenital hematological disorder | 98.39% | DL |
| 11 | septicemic plague | 97.94% | DL |
| 12 | pneumonia | 96.46% | DL |
| 13 | ureter tuberculosis | 96.36% | DL |
| 14 | tumor of testis and paratestis | 96.26% | DL |
| 15 | chondroid hamartoma | 96.14% | DL |
| 16 | ductal or ductular proliferation | 96.14% | DL |
| 17 | non-seminomatous lesion | 96.14% | DL |
| 18 | bronchial adenomas/carcinoids childhood | 96.14% | DL |
| 19 | mesenchymoma | 96.14% | DL |
| 20 | benign neoplasm of tongue | 96.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.